Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 37 citations in OpenAlex.

1. CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.Translational stroke research · 2022
   Article
2. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.Genes · 2019
   Review
3. Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to Cardiovascular Diseases: A Literature Review.Frontiers in public health · 2017
   Review
4. Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions.Therapeutics and clinical risk management · 2015
   Article
5. Pharmacogenetics of antiplatelet therapy.Current atherosclerosis reports · 2014
   Review
6. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Current opinion in cardiology · 2013
   Review
7. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.Clinical pharmacology and therapeutics · 2012
   Article
8. Genetics of peripheral artery disease.Circulation · 2012
   Review
9. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.Pharmacogenomics · 2012
   Review
10. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest · 2012
    Review
11. A review of pharmacogenetics of adverse drug reactions in elderly people.Drug safety · 2012
    Review
12. Pharmacogenomics: application to the management of cardiovascular disease.Clinical pharmacology and therapeutics · 2011
    Article
13. The pharmacogenetics of antiplatelet agents: towards personalized therapy?Nature reviews. Cardiology · 2011
    Review
14. Ticagrelor: a review of its use in the management of acute coronary syndromes.Drugs · 2011
    Review
15. Genomics and drug response.The New England journal of medicine · 2011
    Review
16. CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.Indian heart journal
    Article

Corrections and comments

• Comment on
  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.2010

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as